Indiana University School Of Medicine

Climb Bio appoints Douglas E. Williams, Ph.D., as Chair of its Board of Directors, leveraging his 30+ years of biotech leadership experience, including roles at Sana Biotechnology, Codiak BioSciences, and Biogen. Williams' expertise in immunology drug development will support Climb Bio's mission to improve treatments for immune-mediated diseases, focusing on the company's lead candidate, budoprutug.

John Sims presented at CTAD that starting donanemab at low doses and titrating up reduced ARIA-E by 40%, especially for APOE homozygotes. Gil Rabinovici's new donanemab AUR emphasize stricter MRI criteria for safety. Lilly plans to submit data to update the label.

New guidelines for AI use in brain cancer diagnosis and treatment ensure reliable clinical trial results and patient protection, addressing variability in radiologist interpretations and promoting objective AI analysis of tumor images.

Adipo Therapeutics presented data on ADPO-002's impact on mitochondrial biogenesis and adipocyte browning, supporting its potential for treating obesity and metabolic disorders, and advancing to Phase I clinical trials.

Antibiotic prophylaxis may protect kidneys of kids with vesicoureteral reflux during febrile UTIs, as per the RIVUR trial analysis. Children not on prophylaxis showed a significant eGFR decline, while those on prophylaxis did not. This suggests UTIs affect kidney function at a microscopic level, not just macroscopically monitored by DMSA scans.

Semaglutide, found in Ozempic and Wegovy, reduced Alzheimer’s risk in Type 2 diabetes patients, per a study in Alzheimer’s & Dementia. This adds to evidence that GLP-1 drugs may benefit the brain. Novo Nordisk’s phase 3 trials on semaglutide for mild cognitive impairment or early-stage Alzheimer’s are ongoing, with results expected next year. If positive, semaglutide could offer a new preventive treatment option.

Novo Nordisk researchers developed NNC2215, a glucose-sensitive insulin with auto-adjustable bioactivity, addressing a 50-year-old challenge. NNC2215, using macrocycles, shows increased insulin receptor binding affinity with rising glucose levels, protecting against hypoglycemia in animal models. This innovation promises to improve diabetes treatment by lowering hypoglycemia risk and partially covering the need for fast-acting insulin.

RSV vaccine provided 80% protection against severe disease, hospitalization, ICU admission, and death in adults 60+ during the 2023–24 season, according to a CDC-led study in The Lancet. The study, using real-world data, found the vaccine particularly effective in those 75+.

A real-world study confirms RSV vaccines, Arexvy and Abrysvo, offer 80% protection against severe illness and hospitalization for seniors aged 60 and over, with significant benefits for those 75 and older. Published in The Lancet, the study highlights the vaccine's effectiveness and potential cost savings.

Real-world study confirms RSV vaccine offers 80% protection against severe illness/hospitalization for seniors aged 60 and over, with significant benefits for those aged 75+.